All News about Immunovant Inc
![](https://www.investors.com/wp-content/uploads/2024/05/Stock-Immunovant-01-shutt.jpg)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/05/29/BHVN.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/05/29/Movers_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Recap: Immunovant Q3 Earnings
February 12, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/05/29/untitled_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2017/11/Stock-drugVials-01-adobe.jpg)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://www.investors.com/wp-content/uploads/2023/10/Stock-argenx-01-shutt.jpg)
![](https://www.investors.com/wp-content/uploads/2023/10/Stock-argenx-01-shutt.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_0.jpeg?width=1200&height=800&fit=crop)
Analyst Ratings for Immunovant
December 01, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.png?width=1200&height=800&fit=crop)
Where Immunovant Stands With Analysts
November 15, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_3.png?width=1200&height=800&fit=crop)
Recap: Immunovant Q2 Earnings
November 09, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://investorplace.com/wp-content/uploads/2019/07/biotech1600molecule.jpg)
![](https://investorplace.com/wp-content/uploads/2023/12/russell-2000-1600.png)
![](https://investorplace.com/wp-content/uploads/2023/12/russell-2000-1600.png)
![](https://g.foolcdn.com/editorial/images/761232/biotech-researcher.jpg)
![](https://www.investors.com/wp-content/uploads/2020/12/Stock-ChristmasTree-NYSE-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/21/image42.jpg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/12/Stock-DrugDesigner-01-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/12/21/imvt.png?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/12/21/amazon_-logo.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/12/21/image15.jpg?width=1200&height=800&fit=crop)
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
December 21, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities
![](https://ml.globenewswire.com/media/f1a5db68-ee4f-437f-b4e6-2b840ae6a536/small/roivantlogo-png.png)
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023
From Roivant Sciences
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2023/12/20/image34.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/12/20/image30.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2023/11/Stock-cybertruck-new-01-company.jpg)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.